BDC31CC4-927C-49B1-819B-5119AA8422E8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 22.404730617608408
- age_years
- 53
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.549
- MYC_TARGETS_V1+0.490
- UNFOLDED_PROTEIN_RESPONSE+0.453
- PROTEIN_SECRETION+0.448
- TGF_BETA_SIGNALING+0.440
- ANDROGEN_RESPONSE+0.436
- CHOLESTEROL_HOMEOSTASIS+0.421
- G2M_CHECKPOINT+0.392
- DNA_REPAIR+0.372
- MTORC1_SIGNALING+0.365
Top 10 suppressed
- KRAS_SIGNALING_DN-0.436
- SPERMATOGENESIS-0.370
- MYOGENESIS-0.239
- APICAL_SURFACE-0.200
- BILE_ACID_METABOLISM-0.176
- ESTROGEN_RESPONSE_LATE-0.171
- COAGULATION-0.140
- PANCREAS_BETA_CELLS-0.135
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.088
- ALLOGRAFT_REJECTION-0.073
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934719 | — | — | 0.922 |
| 2 | AB522ACF-5D84-41B0-9671-CE2511EBD94F | — | — | 0.904 |
| 3 | 4BB9587B-88CB-4BD9-BE1D-2CDF61337579 | — | — | 0.900 |
| 4 | F226F6D3-DE88-4B15-A0F1-63EDB55E8F9D | — | — | 0.896 |
| 5 | SRR934930 | — | — | 0.892 |
| 6 | 745233F1-DF41-4DDA-9146-1666DD59355E | — | — | 0.892 |
| 7 | SRR934861 | — | — | 0.887 |
| 8 | SRR934827 | — | — | 0.885 |
| 9 | SRR934817 | — | — | 0.885 |
| 10 | 67B2F9CD-759E-4300-8F4B-1B5C4F9E0B1C | — | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.549 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.453 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.448 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.440 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.436 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.421 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.392 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.372 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.365 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.339 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.329 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.329 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.296 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.281 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.256 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.256 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.249 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.243 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.234 | Inavolisib | — uncovered |